Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Lupus Erythematosus, Systemic 1

Interventions

Rituximab 16Cyclophosphamide 12fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Vincristine 5Radiotherapy 5Prednisone 5Lenalidomide 5Etoposide 5Doxorubicin 5Cytarabine 5Bendamustine Hydrochloride 5fludarabine 4Whole-Body Irradiation 4Filgrastim 4tazemetostat 3Mycophenolic Acid 3Melphalan 3Carmustine 3umbralisib 2ublituximab 2sargramostim 2parsaclisib 2ofatumumab 2ibritumomab tiuxetan 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Follicular × gusacitinib × Clear all
NCT06238531 2025-03-13

A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Lymphoid

Lupus Erythematosus, Systemic, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡